Correction & Withdrawal Policies
Article Processing Charges (APC)
Clinical Trials and Reporting guidelines
[1] Galanello, R., Origa, R., 2010. Beta-thalassemia. Orphanet Journal of Rare Diseases. 5(1), 11.
[2] Mishra, A.K., Tiwari, A., 2013. Iron overload in beta thalassaemia major and intermedia patients. Maedica. 8(4), 328.
[3] Porter, J.B., 2005. Monitoring and treatment of iron overload: state of the art and new approaches. Seminars in Hematology. 42(2 Suppl 1), S14-18.
[4] Andrews, N.C., 1999. Disorders of iron metabolism. New England Journal of Medicine. 341(26), 1986- 1995.
[5] Chern, J.P., Lin, K.H., Tsai, W.Y., et al., 2003. Hypogonadotropic hypogonadism and hematologic phenotype in patients with transfusion-dependent beta-thalassemia. Journal of Pediatric Hematology /Oncology. 25(11), 880-884.
[6] Giardina, P.J., Grady, R.W., 1995. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Seminars in hematology. 32(4), 304-312.
[7] De Virgillis, S., Congia, M., Frau, F., et al., 1988. Deferoxamine-induced growth retardation in patients with thalassemia major. The Journal of Pediatrics. 113(4), 661-669.
[8] Bielinski, B.K., Darbyshire, P., Mathers, L., et al., 2001. Bone density in the Asian thalassaemic population: a cross-sectional review. Acta Paediatrica. 90(11), 1262-1266.
[9] Haidar, R., Musallam, K.M., Taher, A.T., 2011. Bone disease and skeletal complications in patients with β thalassemia major. Bone. 48(3), 425-432.
[10] Root, A.W., Diamond, F.B., 2002. Calcium metabolism, normal homeostasis and disorders of calcium metabolism in the child and adolescent. Sperling MA, editor. Pediatric endocrinology. 2nd ed. Philadelphia: Saunders. pp. 65-110.
[11] Soliman, A., De Sanctis, V., Yassin, M., 2013. Vitamin D status in thalassemia major: an update. Mediterranean Journal of Hematology and Infectious Diseases. 5(1).
[12] Blake, G.M., Fogelman, I., 2007. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgraduate Medical Journal. 83(982), 509-517.
[13] Altrichter, S., Boodstein, N., Maurer, M., 2009. Matrix metalloproteinase‐9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients? Allergy. 64(4), 652-656.
[14] Vogiatzi, M.G., Macklin, E.A., Fung, E.B., et al., 2009. Bone disease in thalassemia: a frequent and still unresolved problem. Journal of Bone and Mineral Research. 24(3), 543-557.
[15] Anapliotou, M.L., Kastanias, I.T., Psara, P., et al., 1995. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clinical Endocrinology. 42(3), 279-287.
[16] Benigno, V., Bertelloni, S., Baroncelli, G.I., et al.,2003. Effects of thalassemia major on bone mineral density in late adolescence. Journal of Pediatric Endocrinology & Metabolism. 16(Suppl 2), 337-342.
[17] Voskaridou, E., Terpos, E., 2008. Pathogenesis and management of osteoporosis in thalassemia. Pediatric Endocrinology Reviews: PER. 6, 86-93.
[18] Rothman, M.S., Wierman, M.E., 2008. Female hypogonadism: evaluation of the hypothalamic–pituitary– ovarian axis. Pituitary. 11(2), 163.
[19] Emerit, J., Beaumont, C., Trivin, F., 2001. Iron metabolism, free radicals, and oxidative injury. Biomedicine & Pharmacotherapy. 55(6), 333-339.
[20] Okman-Kilic, T., 2015. Conference proceedings. Estrogen Deficiency and Osteoporosis.
[21] Srisukh, S., Ongphiphadhanakul, B., Bunnag, P., 2016. Hypogonadism in thalassemia major patients. Journal of Clinical & Translational Endocrinology. 5, 42-45.
[22] Wang, L., Li, Q., Duan, X.L., et al., 2005. Effects of extracellular iron concentration on calcium absorption and relationship between Ca2+ and cell apoptosis in Caco-2 cells. World Journal of Gastroenterology: WJG. 11(19), 2916.
[23] Sahota, O., 2000. Osteoporosis and the role of vitamin D and calcium-vitamin D deficiency, vitamin D insufficiency and vitamin D sufficiency. Age and Ageing. 29(4), 301-304.
[24] Rodrıguez-Martınez, M.A., Garcıa-Cohen, E.C., 2002. Role of Ca2+ and vitamin D in the prevention and treatment of osteoporosis. Pharmacology & therapeutics. 93(1), 37-49.
[25] Mills, E.G., Yang, L., Nielsen, M.F., et al., 2021. The Relationship between Bone and Reproductive Hormones beyond Estrogens and Androgens. Endocrine Review. 42(6), 691-719.
[26] Wang, J., Zhang, W., Yu, C., et al., 2015. Follicle-stimulating hormone increases the risk of postmenopausal osteoporosis by stimulating osteoclast differentiation. PLoS One. 10(8), e0134986.
[27] Liu, Z., Ye, F., Zhang, H., et al., 2013. The association between the levels of serum ferritin and sex hormones in a large scale of Chinese male population. PloS one. 8(10), e75908.
[28] Berge, L.N., Bønaa, K.H., Nordøy, A., 1994. Serum ferritin, sex hormones, and cardiovascular risk factors in healthy women. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology. 14(6), 857-861.
[29] Xu, Z.R., Wang, A.H., Wu, X.P., et al., 2009. Relationship of age-related concentrations of serum FSH and LH with bone mineral density, prevalence of osteoporosis in native Chinese women. Clinica Chimica Acta. 400(1-2).
[30] Dhanwal, D.K., 2011. Thyroid disorders and bone mineral metabolism. Indian Journal of Endocrinology and Metabolism. 15(Suppl2), S107.
[31] Ahn, H.Y., 2018. Effects of Abnormal Thyroid Function Status to Bone Metabolism. International Journal of Thyroidology. 11(1), 21-25.
[32] Hung, C.L., Yeh, C.C., Sung, P.S., et al., 2018. Is Partial or Total Thyroidectomy Associated with Risk of Long-Term Osteoporosis: A Nationwide Population-Based Study. World Journal of Surgery. 14, 1-8.
[33] Kim, C.W., Hong, S., Oh, S.H., et al., 2015. Change of bone mineral density and biochemical markers of bone turnover in patients on suppressive levothyroxine therapy for differentiated thyroid carcinoma. Journal of Bone Metabolism. 22, 135–141.
[34] Kozai, M., Yamamoto, H., Ishiguro, M., et al., 2013. Thyroid hormones decrease plasma 1α, 25-dihydroxyvitamin D levels through transcriptional repression of the renal 25-hydroxyvitamin D3 1α-hydroxylase gene (CYP27B1). Endocrinology. 154(2), 609-622.